id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-268572-uhak283t	Woo, Marcel S.	Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients	2020-07-11		.txt	text/plain	1304	92	51	title: Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients However, few details about the effect of individual immunotherapies have been reported, which could instruct us about the immunological control of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we report on two individuals with underlying neuroimmunological diseases who were under stable rituximab therapy-a B cell-depleting monoclonal antibody [6, 7] -when confirmed COVID-19 developed. Patient 2 was a 68-year-old female with neuromyelitis optica spectrum disorder (NMOSD, diagnosed 2014, EDSS 6.0), who was directly admitted to our intensive care unit (ICU) on March 29th, 2020 with progressive respiratory failure and infection of the urinary tract. She had a B cell count of 25/µL (Ref. 80-500/µL, Supplementary Table 2) at the day of admission and tested negative for SARS-CoV-2-specific antibodies (3.5 AU/mL; Ref. In summary, we report on two patients who developed COVID-19 while under treatment with rituximab due to neuroimmunological diseases. Antibody responses to SARS-CoV-2 in patients with COVID-19	./cache/cord-268572-uhak283t.txt	./txt/cord-268572-uhak283t.txt